On May 14, 2026, Bao Pharma-B (02659) announced that, according to the MSCI index review results published on May 12, 2026, the company has been successfully included as a constituent of the MSCI Global Small Cap Indexes. The relevant adjustment will officially take effect after the market close on May 29, 2026. The MSCI Global Small Cap Indexes are compiled by MSCI Inc. and are designed to measure the performance of representative and investable small- and mid-cap companies across global markets. The MSCI index system is one of the most influential index systems globally, tracked by over $17 trillion in global institutional investor assets, encompassing various professional investment institutions such as sovereign wealth funds, pension funds, mutual funds, and exchange-traded funds (ETFs). Its selection criteria include core metrics like market capitalization, liquidity, industry representation, and corporate governance. Inclusion in this index signifies a further enhancement of Bao Pharma-B's visibility and influence in the global capital markets. It is expected to help attract broader attention from international investors, potentially leading to incremental passive fund allocation, and further improve the stock's market liquidity, trading activity, and international profile.